NASDAQ:VTVT vTv Therapeutics (VTVT) Stock Price, News & Analysis $31.18 +1.10 (+3.66%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$31.14 -0.04 (-0.11%) As of 10/9/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About vTv Therapeutics Stock (NASDAQ:VTVT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get vTv Therapeutics alerts:Sign Up Key Stats Today's Range$30.10▼$31.1850-Day Range$30.00▼$35.3752-Week Range$19.50▼$44.00Volume12,835 shsAverage Volume38,674 shsMarket Capitalization$122.85 millionP/E RatioN/ADividend YieldN/APrice Target$55.83Consensus RatingModerate Buy Company Overview vTv Therapeutics, Inc. (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease. vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease. The company has also investigated other compounds targeting metabolic pathways, including oral treatments that may influence glucose regulation and appetite. Based in the United States, vTv conducts development activities through clinical research and collaborations intended to advance its drug candidates toward potential commercialization. Its products remain investigational and are subject to clinical testing and regulatory review; the company does not currently market an approved therapy.AI Generated. May Contain Errors. Read More vTv Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreVTVT MarketRank™: vTv Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 285th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingvTv Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialvTv Therapeutics has a consensus price target of $55.83, representing about 79.1% upside from its current price of $31.18.Amount of Analyst CoveragevTv Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about vTv Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for vTv Therapeutics are expected to decrease in the coming year, from ($2.35) to ($4.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of vTv Therapeutics is -29.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of vTv Therapeutics is -29.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiovTv Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about vTv Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.23% of the float of vTv Therapeutics has been sold short.Short Interest Ratio / Days to CovervTv Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in vTv Therapeutics has recently decreased by 2.22%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldvTv Therapeutics does not currently pay a dividend.Dividend GrowthvTv Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.24 News SentimentvTv Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for vTv Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows5 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, vTv Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.99% of the stock of vTv Therapeutics is held by insiders.Percentage Held by Institutions17.51% of the stock of vTv Therapeutics is held by institutions.Read more about vTv Therapeutics' insider trading history. Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTVT Stock News HeadlinesvTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026October 10 at 8:54 AM | markets.businessinsider.comvTv Therapeutics stock jumps on FDA orphan drug statusOctober 8 at 4:49 PM | uk.finance.yahoo.comTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Analysts Conflicted on These Healthcare Names: vTv Therapeutics (VTVT) and CSL (OtherCMXHF)October 8 at 6:47 AM | theglobeandmail.comVTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell DiseaseOctober 8 at 6:47 AM | rttnews.comContrasting Milestone Pharmaceuticals (NASDAQ:MIST) and vTv Therapeutics (NASDAQ:VTVT)October 8 at 2:15 AM | americanbankingnews.comvTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell DiseaseOctober 7 at 4:01 PM | globenewswire.comvTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Recommendation of "Moderate Buy" from BrokeragesOctober 7 at 6:29 AM | americanbankingnews.comSee More Headlines VTVT Stock Analysis - Frequently Asked Questions How have VTVT shares performed this year? vTv Therapeutics' stock was trading at $39.99 at the beginning of the year. Since then, VTVT shares have decreased by 22.0% and is now trading at $31.18. How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc. (NASDAQ:VTVT) released its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by $0.08. When did vTv Therapeutics' stock split? vTv Therapeutics shares reverse split before market open on Tuesday, November 21st 2023.The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did vTv Therapeutics IPO? vTv Therapeutics (VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,812,500 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. How do I buy shares of vTv Therapeutics? Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that vTv Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), NIO (NIO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD). Company Calendar Last Earnings8/06/2026Today10/10/2026KOL event10/20/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VTVT's financial health is in the Green zone, according to TradeSmith. VTVT has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VTVT CIK1641489 Webwww.vtvtherapeutics.com Phone(336) 841-0300Fax336-841-0310Employees26Year Founded1998Price Target and Rating Average Price Target for vTv Therapeutics$55.83 High Price Target$67.00 Low Price Target$42.00 Potential Upside/Downside+79.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.97 million Net MarginsN/A Pretax Margin-17.38% Return on Equity-6.27% Return on Assets-5.06% Debt Debt-to-Equity RatioN/A Current Ratio12.48 Quick Ratio12.48 Sales & Book Value Annual Sales$1.02 million Price / Sales120.44 Cash FlowN/A Price / Cash FlowN/A Book Value$16.36 per share Price / Book1.91Miscellaneous Outstanding Shares3,940,000Free Float3,703,000Market Cap$122.85 million OptionableNot Optionable Beta0.21 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:VTVT) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
